The Washington Legal Foundation cautions that the Trump administration’s ongoing crackdown on direct-to-consumer pharmaceutical advertising is on a collision course with First Amendment protections.
The U.S. government urges the Supreme Court to take up a patent-infringement dispute to decide whether generic drugmakers may face liability for inducement of patent infringement when they market a drug under a so-called “skinny label.”
The Washington Legal Foundation cautions that the Trump administration’s ongoing crackdown on direct-to-consumer pharmaceutical advertising is on a collision course with First Amendment protections.
The U.S. government urges the Supreme Court to take up a patent-infringement dispute to decide whether generic drugmakers may face liability for inducement of patent infringement when they market a drug under a so-called “skinny label.”
Researchers say that the enhanced FDA regulatory authority from the 2017 FDA Amendments Act did not significantly change the time to first agency postmarket safety action for novel therapeutics.
Children’s Health Defense asks FDA to revoke BLA approvals for all Pfizer and Moderna mRNA Covid-19 vaccines, claiming they do not comply with BLA requirements for clinical trials and are mislabeled, misbranded, and potentially adulterated.
